CHANGING THE FUTURE
OF CANCER TREATMENT
FUTURE
LIBI-Diagnostics is a gene-biomarker start-up for early detection of cancer, powered by the next-generation bio-liquid test.
Learn more about LIBI
LIBI Diagnostics is a gene-biomarker start-up for the early detection of cancer, powered by next-generation bio-liquid tests.
At LIBI we aim to identify the development of cancer cells in their early stages through the development of a fluid body test. This helps control and prevent the formation of tumors in the body. Doing so increases the chances of survival for cancer patients.

This kind of testing does not currently exist at all. Our aim is to make LIBI testing an industry standard - detecting cancer in a non-invasive way, before it is too late.
Reduce Cancer mortality through early diagnosis and early treatment.

When identified early, cancer is more likely to respond to treatment and can result in a greater chance of survival, as well as the use of less expensive treatment. Significant improvements can be made in the lives of cancer patients by detecting cancer early and reducing delays in care.

Early diagnosis consists of three components
Why early detection is important
cancer cases worldwide
19.3 M
breast cancer cases
2.26 M
cancer deaths worldwide
10 M
lung cancer cases
2.21 M
Being aware of cancer symptoms and seeking medical advice if you are experiencing any of these symptoms
Access to diagnostic services and clinical evaluation
Regular and consistent referrals to treatment services.
Making it essential that cancer programmes are designed for early detection and accurate diagnosis to ensure that the most effective treatment can be used when it matters most.

At LIBI, we believe that the aggressive use of drugs and radiation can become irrelevant. Using our technology, we will identify the development of cancer cells in the early stages and allow control and prevention of the formation of tumors in the body by matching biological and immunotherapy treatment to each patient. Doing so will increase the chances of survival of cancer patients.
Early diagnosis of cancer is crucial in most types of cancers.
Learn More
MRE

(Technion, Israel Institute of Technology)
David Risin
Co-Founder & CEO
Ganjam V. Kalpana, Ph.D.
Principal Investigator
Mark Trauner Faculty Scholar in Neuro-Oncology
Professor, Department of Genetics
Professor, Department of Microbiology and Immunology
Albert Einstein College of Medicine
Dr.Ayelet Ben Barak
Co-Founder & CMO
Senior physician in Pediatric
Hematology-Oncology
The former head of the hematology unit at Rambam Hospital
M.D.
(Technion, Israel Institute of Technology)
LIBI Diagnostics Leadership
STAY UPDATED